Part 5 of 6: A poorly implemented Risk Management Program (RMP) can erode trust, increase risks, and jeopardise outcomes. Learn how thoughtful design and technology can enhance patient safety, regulatory…
Understanding the unique value proposition and buyer segmentation to develop investor ready research for a global hardware and SaMD company
Commercial Eyes’ client, Vitrafy has successfully completed their initial public offering (IPO) on the Australian Securities Exchange (ASX).
We unpack the work Commercial Eyes delivered to inform and support the development…
Making the Right Call: Commercial Eyes’ Expertise in Assessing In-Licensing Opportunities
At Commercial Eyes, we empower our clients to make informed, confident decisions about whether to license a product by offering comprehensive, data-driven assessments that balance clinical promise with commercial viability….
Delivering Critical Therapies to Patients in Need through Managed Access Programs? Expert execution makes all the difference.
Outsourcing Managed Access Programs (MAPs) to specialised partners like Commercial Eyes offers pharmaceutical companies the significant advantage of freeing up internal staff time while ensuring ongoing compliance and…
Empowering Patients with Comprehensive Support: How Commercial Eyes’ Patient Support Programs Make a Difference
In part three of our six-part series, we focus on how the right design of Patient Support Programs (PSPs) empowers patients and improves outcomes in their treatment journey. At Commercial…
In part two of our six-part series, we dive deeper into Access Programs, which, at their heart, play a pivotal role in bringing innovative treatments to patients prior to launch….
Enhancing Health Outcomes through Patient Programs
In this 6-part series, we explore how Commercial Eyes designs and delivers a range of different patient programs to address the multifaceted challenges that Healthcare Professionals and patients can encounter…